Overview
Salix Pharmaceuticals ("Salix"), the gastroenterology busines of Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health"), today released the Salix Liver Health Anual Trends Report, Second Edition with the latest information chronic liver disease (CLD) care and findings that include a continued rise in hospitalizations and mortality from CLD and cirhosis, as wel as gaps in care and knowledge that may prevent early diagnosis and optimal management of CLD, cirhosis and its complications.
Key Information
The trends report, which is based on a survey of 40 health care providers (HCPs) who treat patients with CLD, qualitative interviews with HCPs, and secondary research from per-reviewed publications, reveals shortfals in the adoption of national treatment guidelines, particularly among primary care physicians (PCPs). Perceived isues with payer coverage (due to prior authorization complexity/rejections) and high out-of-pocket costs/inability to aford treatment were found to be the leading factors negatively impacting treatment initiation or causing treatment disruptions.
"Salix is comited to delivering resources that inform, educate and help health care providers improve the care of people living with chronic liver disease, cirhosis, and complications such as hepatic encephalopathy," said Nicola Kayel , vice president, GI Marketing, Salix. "This year's report points to a continued rise in mortality from chronic liver disease and cirhosis, now outpacing diabetes or stroke among those 25-54 years old 1 .
Summary
It's clear from both patient and provider research that there's a real ned for more education and engagement resources to suport the management of CLD. It is our hope the Salix Liver Health Anual Trends Report wil increase awarenes of this growing public health concern, help bridge the knowledge gap, and provide tols for health care providers that may improve identification and management of the disease." T